Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko Phytofare Factory
02 April 2014 - 12:00AM
Marketwired
Plandai Biotechnology, Inc. Commissions Stage 2 of Senteeko
Phytofare Factory
Factory Set to Commence Operating in April 2014
SEATTLE, WA--(Marketwired - Apr 1, 2014) - Plandaí
Biotechnology, Inc. (OTCQB: PLPL), a producer of highly
bioavailable plant extracts for industries including health,
wellness, nutraceutical, and pharmaceutical, today announced that
it has completed and successfully optimized Stage 2 of its
state-of-the-art production facility on the Senteeko Tea Estate in
South Africa. Section 2 is the critical stage of the factory's
operations as it is in this section that the hydrodynamic sheering
process takes place.
As previously disclosed, Plandaí's unique extraction system uses
live plant material and a combination of temperature and a unique
wave of acoustic energy to release the living phytonutrients,
rearranging the polyenes into a bio-compatible form. Stage 3
of the process then separates out the solids and any unnecessary
elements, rendering pharmaceutical-grade, purified catechins in
mainly nano-particle form. This Phytofare™ Catechin complex
can then be sold "as is" as an ingredient for nutraceuticals and
cosmetics or further processed by incorporating it into a Pheroid®
emulsion. The Pheroid™ serves to protect the Phytofare™ as it
passes through the GI tract or can enhance topical absorption.
Plandaí's engineering team is currently working to complete
Stage 3 and supporting infrastructures, including the boiler and
computer automation system, which should brought online during
April 2014. The final commissioning will take place this month
as the company's engineers and scientists fine-tune the equipment,
train staff, and test the output for conformity with the product
profile.
Chairman and Chief Executive Officer Roger Duffield commented,
"Having successfully commissioned Stage 2, the one of a kind system
is now complete. The magic of Phytofare involves unzipping the
molecule to release the valuable phytonutrients, which we have now
done for the first time on an industrial scale. Stage 3 should
shortly come online once the computer system is in place and the
final pieces are connected. It is exciting to see the
culmination of over ten years of research and effort on the part of
countless supporters."
The first product Plandaí will bring to the market is Phytofare™
Catechin Complex, which includes the entire catechin profile
derived from green tea. Stages 2 and 3 are also set up to
process lemons, which will lead to the introduction of Phytofare™
Limonoid Glycoside Complex later in the year. Citrus
bioflavonoids are highly regarded not only for treating cold and
flu symptoms but also as a potent anti-inflammatory useful for
soft-tissue injuries and sports recovery.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly
bioavailable, phytonutrient rich extracts which are being utilized
to deliver a new family of drugs to safely and affordably treat a
multitude of diseases and conditions. Plandaí Biotechnology
controls every aspect of the process, from growing the raw
materials on its farms in South Africa, to producing its patented
Phytofare™ extracts in-house, allowing the Company to guarantee the
continuity of supply as well as quality control throughout the
entire process. Targeted industries for the Company's products
include beverage, cosmeceutical, wellness, nutraceutical,
anti-aging, and pharmaceutical. For more information, please
visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements
and involve risks and uncertainties. Results, events and
performances could vary from those contemplated. These statements
involve risks and uncertainties which may cause actual results,
expressed or implied, to differ from predicted outcomes. Risks and
uncertainties include product demand, market competition, and
Plandaí's ability to meet current or future plans. Investors should
study and understand all risks before making an investment
decision. Readers are recommended not to place undue reliance on
forward-looking statements or information. Plandaí is not obliged
to publicly release revisions to any forward-looking statement, to
reflect events or circumstances afterward, or to disclose
unanticipated occurrences, except as required under applicable
laws.
Contact: Andrew Beyer Phone: Toll Free 888-627-6902 Email:
investor@Plandaíbiotech.com
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Dec 2024 to Jan 2025
Plandai Biotechnology (PK) (USOTC:PLPL)
Historical Stock Chart
From Jan 2024 to Jan 2025
